Roberto Lorusso News Today

The Middlesex-London Health Unit opened a clinic at Western Fair District Friday, and the first two days were full. In fact, the appointments are booked through next week.

Data from a North American registry show anemia can affect more than 75% of candidates for a left ventricular device implant and up to 67% of recipients in the years after implant, driving higher mortality risk and worse quality of life.“Despite the increasing awareness regarding end-stage HF and its treatments, the role and impact of anemia remain an under-investigated question at

Only four days before the release of Nevermind, LoRusso held a sit down interview with the Nirvana lead singer, the date was September 20th, 1991.

We read with great interest the EuroECMO-COVID study1 in The Lancet Respiratory Medicine. Roberto Lorusso and colleagues should be congratulated for this important research, which contributes to our understanding of the long-term outcomes of COVID-19 in the most severe forms of disease treated with extracorporeal membrane oxygenation (ECMO). However, we would like to draw attention to missing data that could have had a key role in lung recovery, extended ECMO duration, and associated complicatio...

Experts also call for more data, especially in high-risk patients, to clarify the best diagnosis and treatment options for this cohort.

Accurately selecting patients who are likely to benefit from venovenous extracorporeal membrane oxygenation (VV-ECMO) for severe respiratory failure is crucial given its low availability, substantial invasiveness, associated complications, and high financial costs. Existing selection criteria are influenced by multidimensional factors, including local logistics and geographical variation in health-care provision, expert opinion, and data from observational studies and a single randomised control...

/PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac...

/PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac...